Skip to site services
Skip to top navigation
Skip to main content
Skip to footer
Alert service | Downloads | Glossary | Print this page Print this page | Site map
Vectura is developing inhaled pharmaceuticals and has two key franchises: respiratory and neurology
Vectura is a leader in the development of inhaled pharmaceuticals, using ideas, technologies and skills to create products to treat respiratory, neurological and other diseases – rapidly and effectively. Our goal is to improve patients’ lives and generate value for our stakeholders.

Share price

50.25 GBp  +1.00 VEC.L
Market cap GB£ 155
Date 09/05/2008
 Share price information

Next events

22 May 2008 
Prelim Results for Year Ending 31 March 2008 28 May 2008 
UBS Global Specialty and Generic Pharma Conference, London  Investor Calendar
Delivered by Investis logo and link to website (opens in a new window)